Surrozen to Present at Upcoming Healthcare Investor Conference
Rhea-AI Summary
Surrozen (Nasdaq: SRZN) will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 at 1:30 PM ET / 10:30 AM PT. Management will deliver a live presentation and audio webcast.
According to the company, the live audio webcast is available via the Investors section of Surrozen's website and a replay will be archived for at least 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – SRZN
On the day this news was published, SRZN declined 10.15%, reflecting a significant negative market reaction. Argus tracked a peak move of +2.1% during that session. Argus tracked a trough of -8.0% from its starting point during tracking. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $25M from the company's valuation, bringing the market cap to $218M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Momentum scanner shows only 1 peer in motion (ANIX) and 0 peers moving in the same direction as SRZN, indicating this looks more stock-specific than a broad biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 25 | Investor conferences | Neutral | +2.7% | Announcement of two early-December 2025 healthcare investor conference appearances. |
| Nov 12 | Inducement stock option | Neutral | -6.3% | Inducement option grant of 50,000 shares to newly appointed CFO. |
| Nov 07 | Quarterly earnings update | Negative | -3.3% | Q3 2025 results with cash balance and sizeable net loss disclosure. |
| Nov 05 | Investor conference | Neutral | +0.6% | Guggenheim healthcare innovation conference presentation announcement. |
| Sep 04 | Inducement grants | Neutral | -2.0% | Inducement stock option grants to four new non-executive employees. |
Past conference and corporate updates for SRZN have generally led to modest, directionally aligned price moves without large dislocations.
Over the last six months, Surrozen has issued a mix of corporate, conference, and financial updates. These include multiple investor conference appearances, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and Q3 2025 results showing cash of $81.3M and a net loss of $71.6M. Price reactions to these events have typically been moderate, with modest gains around conference announcements and small declines around earnings and inducement-related news, suggesting incremental rather than transformational impacts.
Market Pulse Summary
The stock dropped -10.2% in the session following this news. A negative reaction despite this routine conference announcement would contrast with historically modest moves around similar updates. Before the news, SRZN traded at 23.65, above its 200-day MA 13.06 and within about 5% of its 52-week high of 24.9399. Past news flow, including conferences and grants, generally led to moderate, aligned moves, so a sharper decline could reflect profit-taking rather than a direct response to this event.
Key Terms
wnt signaling medical
ophthalmic medical
webcast technical
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Surrozen, Inc. (“Surrozen” or the “Company”) (Nasdaq: SRZN), a biotechnology company pioneering targeted therapeutics to harness the power of Wnt signaling to address the underlying drivers of disease in sight-threatening ophthalmic conditions, today announced that Company management will present at an upcoming healthcare investor conference.
Guggenheim Emerging Outlook: Biotech Summit 2026 on Thursday, February 12, 2026
Presentation at 1:30 PM Eastern Time / 10:30 AM Pacific Time
Interested parties may access the live audio webcast for the conference via the Investors section of the Surrozen website at https://investors.surrozen.com/events-presentations/events-calendar. A replay of the webcasts will be archived on the website at www.surrozen.com for at least 30 days.
About Surrozen
Surrozen is a biotechnology company, pioneering a new class of Wnt-based therapeutics designed to harness the power of Wnt signaling to treat sight-threatening ophthalmic conditions. Built on deep scientific expertise and a proprietary antibody-engineering platform, Surrozen develops multifunctional biologics that selectively activate Wnt signaling in combination with other key disease pathways. Our approach aims to deliver best-in-class, durable therapies that have the potential to transform patient outcomes in some of the most pressing unmet medical needs in ocular diseases. For more information, visit www.surrozen.com.
Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are accompanied by words such as “will,” “plan,” “intend,” “potential,” “expect,” “could,” or the negative of these words and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding Surrozen’s discovery, research and development activities, in particular its development plans for its product candidates (including anticipated clinical development plans and timelines, the availability of data, the potential for such product candidates to be used to treat human disease or address unmet needs in serious eye diseases, as well as the potential benefits and potential differentiation from existing therapies of such product candidates). These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management of Surrozen and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on as a guarantee, an assurance, a prediction, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Surrozen. These forward-looking statements are subject to a number of risks and uncertainties, including the initiation, cost, timing, progress and results of research and development activities, preclinical and clinical trials with respect to its product candidates and potential future drug candidates; the Company’s ability to fund its preclinical and clinical trials and development efforts, whether with existing funds or through additional fundraising; Surrozen’s ability to identify, develop and commercialize drug candidates; Surrozen’s ability to successfully complete preclinical and clinical studies for its product candidates; the effects that arise from volatility in global economic, political, regulatory and market conditions; and all other factors discussed in Surrozen’s Annual Report on Form 10-K for the year ended December 31, 2024 filed, and Surrozen’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 filed with the Securities and Exchange Commission (“SEC”) under the heading “Risk Factors,” and other documents Surrozen has filed, or will file, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Surrozen presently does not know, or that Surrozen currently believes are immaterial, that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Surrozen’s expectations, plans, or forecasts of future events and views as of the date of this press release. Surrozen anticipates that subsequent events and developments will cause its assessments to change. However, while Surrozen may elect to update these forward-looking statements at some point in the future, Surrozen specifically disclaims any obligation to do so, except as required by law. These forward-looking statements should not be relied upon as representing Surrozen’s assessments of any date after the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.
Investor/Media Contact
Email: Investorinfo@surrozen.com
FAQ
When will Surrozen (SRZN) present at the Guggenheim Biotech Summit 2026?
How can investors attend the Surrozen (SRZN) webcast on February 12, 2026?
Will Surrozen (SRZN) make a replay of the Guggenheim presentation available?
What topics will Surrozen (SRZN) likely cover in the investor presentation on February 12, 2026?
Where can I find the Surrozen (SRZN) webcast link and replay after the event?
